Efficacy and Safety of Mexidol® in Stroke Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 304 participants.

Also called NCT06437626

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 304 participants (enrolled count) (from the registry)
Sponsor
  • Pharmasoft Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06437626
Other papers using this trial's data
  • [Multimodal antioxidant therapy in ischemic stroke: from MIR trial to bedside] Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2025 DOI, PubMed 41456191

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Kazakhstan, Russia, Uzbekistan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06437626. Randomized; double masking; primary purpose treatment. Start 2019-11-18 (actual); primary completion 2023-08-18 (actual). Results posted on 2025-12-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Mexidol® in Stroke Therapy
Acronym
MIR
Intervention (Drug)
Mexidol (Ethylmethylhydroxypyridine Succinate)
Intervention (Drug)
Placebo
Lead sponsor
Pharmasoft (class: industry)

Record details

Record id
cardio:ct-nct06437626
Content hash
1a3b8de608a1aa214f95da6a57918dd3437c0f469d2fcbe93dae53b0b74769ab